Full Press Release Details
dupixent dupilumab approved in the european union as the first ever targeted therapy for patients with copd.
REGN
dupixent dupilumab approved in the european union as the first ever targeted therapy for patients with copd
Key Takeaway: dupixent dupilumab approved in the european union as the first ever targeted therapy for patients with copd